Stephen A. Hitchcock
Amgen (United States) · 54 works · 2,404 citations · h-index 26
Top works
- Structure−Brain Exposure Relationships
- A tandem radical macrocyclisation - radical transannulation strategy to the taxane ring system
- Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds
- Synthesis of macrocycles via allylic radical intermediates. A total synthesis of (−)-zearalenone
- Selectivity in palladium(0)-catalyzed cross-coupling reactions: Application to a tandem stille reaction
- From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)
- Targeting cannabinoid agonists for inflammatory and neuropathic pain
- A Convergent Total Synthesis of Calicheamicin γ
- The First Total Synthesis of Bacterial Cell Wall Precursor UDP−N-Acetylmuramyl-Pentapeptide (Park Nucleotide)
- Synthesis and conformational analysis of α,α-difluoroalkyl heteroaryl ethers
- A Remarkable Glycosidation Reaction: The Total Synthesis of Calicheamicin .gamma.1I
- Blood–brain barrier permeability considerations for CNS-targeted compound library design
- On the DNA Recognition Role of the Carbohydrate Sector in Calicheamicin: A Comparison of DNA Cleaving Capacity of Enantiomeric Calicheamicinones
- Design and Preparation of a Potent Series of Hydroxyethylamine Containing β-Secretase Inhibitors That Demonstrate Robust Reduction of Central β-Amyloid
- Eine konvergente Totalsynthese von Calicheamicin γI1
- A tandem radical macrocyclisation-transannular cyclisation approach towards the taxanes
- Total synthesis of the mycotoxin (–)-zearalenone based on macrocyclisation using a cinnamyl radical intermediate
- Discovery and Optimization of a Novel Series ofN-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB2) Agonists
- Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors
- Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors